Search
Madrigal Pharmaceuticals Inc
MDGLAdd to Watchlist
399.630USD
-0.470-0.12%
Close 11-06 16:00（ET）
9.23BMarket Cap
LossP/E TTM
After-hours 17:31 (ET)402.950USD+3.210+0.80%
After-hours 17:31 (ET)Madrigal Pharmaceuticals Inc (MDGL) Stock Price Target & Forecast
Analyst Rating
Based on 20 analysts giving stock ratings to Madrigal Pharmaceuticals Inc in the past month.
Buy
5 Strong Buy
14 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
684.947USD+59.16%
MDGL Analyst Recommendation Trends
In the current month, MDGL has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MDGL average Analyst price target in the last month is 684.947.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
3
3
3
3
3
3
14
14
13
12
12
12
12
12
1
1
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
20
18
17
17
17
17
17
MDGL Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, MDGL EPS is projected to reach -0.258 in FY2026Q4, following reported EPS of 1.896 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-4.03
-2.57
-0.88
-0.26
-0.44
Actual
-3.25
-1.99
1.90
--
--
Surprise
+19.31%
+22.52%
+315.96%
--
--
FAQs
What is Madrigal Pharmaceuticals Inc's expected revenue for the next quarter?
Madrigal Pharmaceuticals Inc's expected revenue is 468.96M.
What is Madrigal Pharmaceuticals Inc's price target?
Analysts forecast that Madrigal Pharmaceuticals Inc's price target is USD 688.47, with the highest forecast at USD 962.00 and the lowest forecast at USD 479.00.
How have Madrigal Pharmaceuticals IncMDGL's recent earnings per share performed?
The market expectation was USD 1.90, while Madrigal Pharmaceuticals IncMDGL's earnings per share (EPS) for the previous quarter was USD -1.99. EPS for the next quarter is expected at USD -0.26.
What is the analyst rating for Madrigal Pharmaceuticals Inc?
Based on the ratings of Madrigal Pharmaceuticals Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.